The startup founded by Google DeepMind to accelerate the discovery of new medicines is looking to secure fresh capital from investors to scale its computational platform. The company is in discussions to raise about $5B in new funding, which would value Isomorphic Labs at roughly $50B, according to people familiar with the matter. Despite the valuation, the company has not yet tested any of its AI-designed drugs in human patients.
Isomorphic Labs uses a drug-design engine based on AlphaFold 3 to predict protein folding and determine how candidate molecules bind to targets, allowing chemists to filter out weak designs before proceeding to expensive lab synthesis and animal studies. The current funding talks follow a $2.1B capital raise the company completed in May.
